BRISTOL, Tenn.– USAntibiotics, the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Eric Wesoloski to the position of vice president of quality and regulatory affairs. In this role, Wesoloski leads all aspects of quality assurance and control, compliance, regulatory affairs and pharmacovigilance related to the manufacturing, packaging, distribution and post-marketing requirements for the company’s antibiotics.
With more than 30 years in the life sciences industry, Wesoloski’s experience spans markets that include biologics, nutraceuticals, medical devices and pharmaceuticals. He is a recognized global quality leader, known for building best-in-class teams and processes that foster operational excellence, adhere to the highest quality standards, and meet U.S. Food and Drug Administration (FDA) regulatory compliance requirements.
“We are pleased to welcome Eric Wesoloski to USAntibiotics as vice president of quality and regulatory affairs,” said Patrick Cashman, president, USAntibiotics. “Eric’s extensive experience in the life sciences industry, coupled with a proven track record of building robust quality assurance systems, reinforces our strong commitment to upholding the highest standards in pharmaceutical manufacturing. As we continue advancing our mission of producing life-saving antibiotics on American soil, we believe his leadership will play a key role in our delivery of these essential medications.”
Prior to joining USAntibiotics, Wesoloski held an array of executive leadership and technical roles, including positions with Regor Pharmaceuticals, Gan & Lee Pharmaceuticals, Takeda Pharmaceuticals and TransCode Therapeutics.
